Likuiditas cepet revmed.com (RVMD)

The critical liquidity trend confirms the potential of Revolution Medicines (RVMD), driven by patents for RAS inhibitors. However, geopolitical fragmentation is hindering global trials, and the implementation of ESG standards for waste disposal requires expenditure. Consequently, the 11.16 level represents the current value of this metric, which clearly demonstrates the company's real solvency excluding inventory.

This ratio assesses the ability of Revolution Medicines (RVMD) to instantaneously settle short-term liabilities using only cash and accounts receivable, excluding slow-moving inventories. For Revolution Medicines, which is building a foundation for RAS inhibitors, the quick ratio confirms financial stability amid the formation of deferred demand from oncology centers, demonstrating a high degree of reliability and the quality of liquid assets.